ConductScience.org, home
All databases
API referenceFor AI assistants

Trial comparisons

Open

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last601 to 620 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion53 of 7,434

44 of 7,330

0.1 points

-0.2 to 0.4

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

ASA 81mg vs ASA 325mg: deaths from any cause315 of 7,434

357 of 7,330

-0.6 points

-1.3 to 0.0

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

ASA 81mg vs ASA 325mg: Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD)590 of 7,434

569 of 7,330

0.2 points

-0.7 to 1.0

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

ASA 81mg vs ASA 325mg: Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG])471 of 7,434

446 of 7,330

0.3 points

-0.5 to 1.0

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

ASA 81mg vs ASA 325mg: serious adverse events383 of 7,434

349 of 7,330

0.4 points

-0.3 to 1.1

14,764NCT02697916

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome Hospitalization for ACS602 of 7,356

570 of 7,396

0.5 points

-0.4 to 1.4

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Primary Safety Outcome MACE Events839 of 7,356

905 of 7,396

-0.8 points

-1.9 to 0.2

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome MI483 of 7,356

493 of 7,396

-0.1 points

-0.9 to 0.7

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Primary Efficacy Outcome MACE Events839 of 7,356

905 of 7,396

-0.8 points

-1.9 to 0.2

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome All-Cause Mortality507 of 7,356

584 of 7,396

-1.0 points

-1.8 to -0.2

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome Hospitalization for HF219 of 7,356

231 of 7,396

-0.1 points

-0.7 to 0.4

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome CV Death340 of 7,356

383 of 7,396

-0.6 points

-1.3 to 0.1

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: Secondary Efficacy Outcome Stroke187 of 7,356

218 of 7,396

-0.4 points

-0.9 to 0.1

14,752NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Asundexian vs Apixaban: Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding17 of 7,373

53 of 7,364

-0.5 points

-0.7 to -0.3

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Fatal Bleeding0 of 7,373

4 of 7,364

-0.1 points

-0.1 to 0.0

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Clinically Relevant Non-major Bleeding67 of 7,373

140 of 7,364

-1.0 points

-1.4 to -0.6

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Intracranial Hemorrhage3 of 7,373

18 of 7,364

-0.2 points

-0.3 to -0.1

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality149 of 7,373

101 of 7,364

0.6 points

0.2 to 1.1

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding120 of 7,373

75 of 7,364

0.6 points

0.2 to 1.0

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Minor Bleeding187 of 7,373

317 of 7,364

-1.8 points

-2.4 to -1.2

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=31

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02697916-a25cdee8",
        "title": "ASA 81mg vs ASA 325mg: Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion",
        "summary": "53 of 7434 against 44 of 7330; risk difference 0.1 points, 95% interval -0.2 to 0.4; NCT02697916, Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term",
        "record": "/library/comparisons/NCT02697916-a25cdee8",
        "nct_id": "NCT02697916",
        "kind": "outcome",
        "participants": 14764,
        "risk_difference": {
          "value": 0.0011266769215297432,
          "lower": -0.001516686326107318,
          "upper": 0.0037916638939561945
        },
        "group_1": "53 of 7,434",
        "group_2": "44 of 7,330",
        "difference": "0.1 points",
        "interval": "-0.2 to 0.4",
        "trial_title": "Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term"
      },
      {
        "id": "NCT02697916-deaths",
        "title": "ASA 81mg vs ASA 325mg: deaths from any cause",
        "summary": "315 of 7434 against 357 of 7330; risk difference -0.6 points, 95% interval -1.3 to 0.0; NCT02697916, Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term",
        "record": "/library/comparisons/NCT02697916-deaths",
        "nct_id": "NCT02697916",
        "kind": "deaths",
        "participants": 14764,
        "risk_difference": {
          "value": -0.006331074987860431,
          "lower": -0.013084899192852118,
          "upper": 0.0003982976223351944
        },
        "group_1": "315 of 7,434",
        "group_2": "357 of 7,330",
        "difference": "-0.6 points",
        "interval": "-1.3 to 0.0",
        "trial_title": "Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=32",
  "request_id": "jqoHewZ_WPyGqdAt"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Related databases

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?
API referenceFor AI assistants